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Highlights




Adipokine inflammation plays a role in autoimmunity initiation in the
thyroid.
PAMP׳s provide an adjuvant signal to overcome tolerance in the
thyroid.
•Sex differences in autoimmunity incidence many be due to adipokine
differences.

Abstract
Autoimmune thyroid diseases (AITDs), predominately Graves ׳disease
and Hashimoto׳s thyroiditis, comprise the most common autoimmune
diseases in humans. Both have the production of anti-thyroid antibody as an
important aspect and both are much more prevalent in females, being at least
10 times more common than in males. Using these two clues, a hypothesis
for the initiation of thyroid autoimmunity is proposed that helps to make the
case that the thyroid is one of the most sensitive sites for autoimmunity and
helps account for the prevalence and the observed sex differences in AITDs
and associated diseases, such as type 1 diabetes and Latent Autoimmune
Diabetes in Adults (LADA).
The primary mechanisms proposed involve the underlying state of
inflammation as a result of the adipokines, especially leptin, TNF-α, and IL-6,
and the receptors able to recognize pathogen-associated molecular patterns
(PAMP׳s) and damage-associated molecular patterns (DAMP׳s) through Tolllike receptors (TLR) and others receptors present on thyrocytes. The
adipokines are produced by adipose tissue, but have hormone-like and
immune modulating properties. As the levels of leptin are significantly higher
in females, an explanation for the sex difference in thyroid autoimmunity
emerges. The ability of the thyrocytes to participate in innate immunity
through the TLR provides an adjuvant-like signal and allows for the action of
other agents, such as environmental factors, viruses, bacteria, and even
stress to provide the initiation step to break tolerance to thyroid self-antigens.
Seeing the thyroid as one of the most sensitive sites for autoimmunity,
means that for many autoimmune disorders, if autoimmunity is present, it is
likely to also be present in the thyroid – and that that condition in the thyroid
was probably earlier. The evidence is seen in multiple autoimmune syndrome.
Keywords: Leptin, Adipokines, Hashimoto׳s thyroiditis, Graves ׳disease,
PAMP׳s

1. Introduction
The thyroid gland can host two common autoimmune diseases,
Graves ׳disease and Hashimoto׳s thyroiditis (autoimmune thyroiditis).
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Graves ׳disease results in hyperthyroidism which has an estimated
prevalence of 80/100,000/year in women and 8/100,000/year in men
in Western countries (McGrogan et al., 2008). The primary cause of
hypothyroidism in the West (where dietary iodine is generally at
sufficient levels) is Hashimoto׳s disease. Hypothyroidism has an
estimated incidence of 2.2/100,000/year for men and
498.4/100,000/year for females in Western countries (McGrogan et
al., 2008). Taken together, autoimmune thyroid diseases (AITDs) are
the most common autoimmune diseases in humans (Hayter and Cook,
2012).
Autoimmune thyroid disease results from the breaking of
tolerance to self-antigens of the thyroid. There appears to be several
ways in which this can happen, including infection, genetic
predisposition (Medici et al., 2014), environment, some drugs
including IFN-α (Tomer et al., 2007), and dietary iodine (Hansen et al.,
2006 and Tomer and Huber, 2009). Although the mechanisms of the
two diseases involve different arms of the immune response for their
primary destructive result (antibody for Graves ׳and cell-mediated
immunity for Hashimoto׳s), there are common pivotal anti-thyroid
antibodies that both serve to characterize the nature of the diseases,
and to allow monitoring of the disease progression as in other
autoimmune diseases (Damoiseaux, 2013). As various anti-thyroid
antibodies need to be generated in both diseases, the nature of their
targets, and the propensity of aspects of the immune response to
react through genetics and environmental influences (Burek and
Taylor, 2009) are clearly involved, although the role of antibody in the
autoimmune destruction of Hashimoto׳s thyroiditis is not understood.
Additional avenues to the breaking of tolerance, probably involving
cross reactivity of antibody due to molecular mimicry, have also been
suggested. These include responses to Candida albicans ( Vojdani et
al., 1996), Bifidobacterium and Lactobacillis species ( Kiseleva et al.,
2011), Helicobacter pylori strains expressing CagA ( Figura et al.,
1999), Yersinia enterocolitica ( Guarneri et al., 2011), Clostridium
botulinum neurotoxin A ( Gregoric et al., 2011), HCV (Tomer and
Villanueva, 2004), and human parvovirus B19 (Mori et al., 2007).
Recently Gammazza et al. (2014) have identified heat shock protein
Hsp60 as another potential mimic which would add stress to the list of
factors potentially involved. Although there is an association with
several potential mimics and associated agents, it has not been
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possible to show a direct establishment of an autoimmune disease in
the thyroid with any agent. Indeed, induced animal models (McLachlan
and Rapoport, 2014) from agents are common (see for instance: Mori
and Yoshida, 2010 and Tomasi et al., 2005) – but most, except in
genetically susceptible individuals (ElRehewy et al., 1981), require an
adjuvant as part of the induction process. This can be an important
hint if one looks for what could provide an adjuvant-like signal in
addition to a mimic. In some sense, how the systems get to the point
at which an autoimmune state eventually results may be more
important to determine than which potential triggers could provide the
initiation (the final step in a chain of steps). There may be many
possible triggers, but unless the system can respond to them and
initiate breaking of tolerance, there is no autoimmune disease.
In this paper, we focus on the foundation that makes possible
AITDs. The hint that this is the fundamental place to begin is in the
large sex difference in the disease. Why women are so much more
likely to develop AITDs has been difficult to establish. The reason for
the sex difference has been examined from many angles, including
genetics related to the X chromosome, pregnancy, and hormones (Lleo
et al., 2008 and Fortunato et al., 2014), but none have been able to
conclusively determine the cause except in genetically rare cases
(McLachlan and Rapoport, 2014). Also, miRNA expression has been
seen to show sex differences, providing yet another potential avenue
for sex differences (reviewed in Dai and Ahmed (2014)). Associations
between AITDs and type 2 diabetes (Coller and Huggins,
1927 and Procaccini et al., 2011) and suggestions that inflammation
may be at the core of both and responsible for the sex differences in
incidence (Thorand et al., 2007).
The sex differences in thyroid autoimmunity emerge at puberty.
It has been noted (Whitacre, 2001) that at puberty, both leptin and
estrogen rise in tandem. Both leptin (Procaccini et al., 2012) and
estrogen (Cutolo et al., 1995) are potent modulators of the immune
response. Leptin has also been suggested as being involved in some
way in the sex differences in incidence of these diseases (Cojocaru et
al., 2013).
Here, we will try to establish an inflammatory cause for the
development of the foundation for thyroid autoimmunity through leptin
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and other adipokines (Carbone et al., 2012), and the ability of thyroid
cells to participate in innate immunity (reviewed in Kawashima et al.
(2011)). The thyroid also seems to be somewhat unique
immunologically. The primary reason for this sensitivity seems due to
the presence of lymphoid tissue akin to secondary lymphoid follicles
with germinal centers in the thyroid autoimmunity (Armengol et al.,
2001). It is expected that this event happens early in the process after
nonspecific responses result in increased lymphocyte infiltration into
the thyroid (Armengol et al., 2003). A second aspect that makes the
thyroid unique among autoimmune target tissues is that it is the only
one with a hormone (TSH) that stimulates its growth (and increased
thyroid antigens). In addition, CD40 expression in thyrocytes – at least
those that are stressed in some way – allows the thyrocytes to
function as antigen presenting cells. This aspect is implicated for
Graves ׳disease. In Hashimoto׳s the specificity may be also through the
link with CD20 B cells which are both implicated in diabetes initiation
and necessary for the production of spontaneous autoimmune
thyroiditis in mice. B-cell depletion also seems to result in the
production of increased Treg cells (and lower levels of autoimmunity in
mice). So, the unique nature appears to be both structural and the
special nature of thyroid antigens and markers.
Discovered in 1994 (Zhang et al., 1994), leptin is one of several
proteins produced in adipose tissue (known as adipokines) that are
believed to play a role in regulating energy intake and energy
expenditure. As such, an association with the thyroid would not be
unexpected. Recent results, however, point to a role for leptin both as
an immune modulator and as a player in the initiation of autoimmune
thyroid disease (Duntas and Biondi, 2013). The nature of the
inflammation seen with leptin׳s influence (Fantuzzi, 2005), the sex
differences in leptin levels (Hickey et al., 1996), innate immunity in
the thyroid (using the Toll-like and other receptors), along with the sex
differences in the nature of the immune response (Bouman et al.,
2005), provide solid testable hypotheses for the observed sex
differences in AITDs. It should be noted that recent results on an Xlinked Toll-like receptor is claimed to determine sex differences in
systemic lupus erythematosus (Umiker et al., 2014).
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2. The thyroid and primary antigens associated
with thyroid autoimmunity
The thyroid has the primary task of producing two hormones,
triiodothyronine (T3) and thyroxine (T4), that are responsible for the
regulation of the metabolism of proteins, carbohydrates and fats. Also
produced are calcitonin and small quantities of neuroendocrine
peptides. The hormones T3 and T4 (especially the active T3) affect
every cell in the body through regulation of oxygen consumption and
metabolism, but they directly and indirectly affect other systems
including the maintenance of homeostasis in blood pressure, digestion,
and reproduction. The control of the production of the thyroid
hormones is through a feedback system involving two hormones in the
brain and receptors in the thyroid. The primary driver of hormone
production is TSH (thyroid stimulating hormone or thyrotropin)
produced by the pituitary. TSH receptors, found primarily on thyroid
epithelial cells, bind TSH, beginning the cascade leading to thyroid
hormone production. The production of TSH is controlled by the
hormone TRH produced in the hypothalamus. The control of thyroid
hormone production is described as involving this HPT (hypothalamus–
pituitary–thyroid) axis.
Several anti-thyroid antibody in AITDs have been identified. For
the purpose of diagnosis, antibody is primarily aimed at thyroglobulin
(Tg), the prohormone of T3 and T4, thyroid peroxidase (TPO), the
enzyme responsible for adding iodine to Tg, and the TSH receptor
(TSHR). Antibody to any of these three primary antigens are
diagnostic for AITDs. For Graves׳, antibody to TSHR causes an agnostic
signal to continue production of thyroid hormone with disturbing the
normal feedback control. In Hashimoto׳s thyroiditis, the primary antithyroid antibody is against TPO. The rise of antibodies to TPO have
been suggested to predict an eventual development of clinical disease
(Hutfless et al., 2011). The direct damage through the antibodyrelated complement system and antibody-dependent cellular
cytotoxicity are not thought to be the primary cause of damage to the
thyroid characteristic in the disease, however. Hashimoto׳s thyroiditis
involves a complicated infiltration and interaction of immune and
thyroid cells (reviewed in Iwona (2011)). Anti-Tg can be found in
either condition, so is not diagnostic – except for the presence of an
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autoimmune disease (Acar et al., 2013 and McLachlan and Rapoport,
2013). A connection among TPO, TPO antibody, and breast cancer
prognosis has been proposed (Muller et al., 2014). A mathematical
description of the clinical progression of Hashimoto׳s thyroiditis can be
found in Pandiyan et al. (2013).

3. Inflammation, leptin, and diabetes
The product of the ob gene, leptin, was discovered in 1994
( Zhang et al., 1994). It was identified as a hormone involved in
appetite control through the leptin receptor. Leptin, produced in white
adipose tissue, affects appetite through a negative feedback loop
involving the leptin receptor in the hypothalamus (reviewed in Arora
and Arora (2008)). It is now known that leptin is one of a number of
hormones, the adipokines, which have many functions – most having
some impact on the thyroid (Cinar and Gurlek, 2013). One effect is
both to alter thyroid function through disruption of the feedback loop
of the HPT axis by altering TRH (Duntas and Biondi, 2013). A second
effect is through inflammation and inflammatory molecules. The direct
effect on the thyroid by inflammatory molecules (primarily TNF-α) can
be seen in two studies: Zaccone et al. (2003) and Chen et al. (2007).
In each, the role of the cytokine in generating autoimmune thyroid
disease in the mouse is highlighted. In Zaccone et al., the role of the
adjuvant is also described – similar to the steps suggested in this
paper.
In this paper, “leptin” will be used as referring to all of the
adipokines in this context, which include leptin, adiponectin, TNF-α,
and IL-6. The discovery that leptin is involved in low-level
inflammation, provides both a marker of adipose tissue that can be
measured, and a source of the inflammation is reviewed in Scotece et
al. (2014).
Leptin plasma levels correlated positively with body fat (Ostlund
et al., 1996), but the relationship with sex is important for this study.
Hickey et al. (1996) found that fasting serum leptin levels were over
twice as high for females as males. This, along with possible effects of
sex hormones, suggests that females should have more possibility of
low-level chronic inflammation complications than men (Bouman et al.,
2005 and Casimir et al., 2010). It should be noted that the study by
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Casimir et al. was completed on children before the effects of
hormones would be expected. The potential suppressive effect of
testosterone also suggests this result (Furman et al., 2014). The
human data on this connection is limited, however. One recent study
by Harpsøe et al. (2014) has identified an association between Body
Mass Index (BMI) (an indirect measure of serum leptin levels), and
several autoimmune diseases. Marzullo et al. (2010) have established
that leptin levels are correlated with thyroid autoimmunity
independent of bioanthromorphic, hormonal, or weight-related
measures.
The interplay between thyroid disease and leptin in development
of diabetes is complicated by several interacting systems (Hage et al.,
2011). In terms of inflammation and thyroid, metabolic syndrome is
clearly associated, for instance see Shantha et al. (2009) and Ruhla et
al. (2010). The transition from metabolic syndrome to type 2 diabetes
is a well-known risk. A fraction (about 10%) of these type 2 or
metabolic syndrome is eventually recognized as Latent Autoimmune
Diabetes in Adults (Unger, 2007), an autoimmune disease associated
(as is type 1 diabetes) with thyroid autoimmunity (Koch, 2011).

4. Innate immunity and the pattern recognition
receptors (PRR) in the thyroid
Besides the role of leptin in providing a signal which triggers
inflammation and affecting the HPT axis, the native thyroid cells,
thyrocytes, also play a role in the innate immune system. Thyrocytes
have the ability to recognize and respond to pathogen-associated
molecular patterns (PAMP) through PRR. The PRR׳s include Toll-like
receptors, Nod-like receptors and many others (reviewed in
Kawashima et al. (2011)). Thyrocytes also have the ability to respond
to damage-associated molecular patterns (DAMP) coming from cellular
damage (Kawashima et al., 2011) – especially a response to double
stranded DNA and/or RNA. The response of thyrocytes to these
patterns plays two roles in this setting. One is to further increase the
presence of inflammatory cytokines, TNF-α, IL-1, and IL-6, to promote
a specific immune response. Toll-like receptors have been described as
adjuvant receptors (Kaisho and Akira, 2002). The second is the
presentation of self-antigens in association with MHCII expression on
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thyroid cells (Kawashima et al., 2013). Inflammatory molecules have
been recognized with a breaking of tolerance in the context of thyroid
autoimmunity with a like-self (or self) antigen (Akeno et al., 2011).
The identified mimics now have the stage set to overcome selftolerance. Note that if mimics are presented in the system in most
animal models without an adjuvant signal, they are not able to
generate autoimmunity.
Another aspect of this response may be in response to stress,
where heat shock protein Hsp60, triggered as a response to the
stresses of many conditions, is a mimic. In addition, the stress
disruption of the Hypothalamic–Pituitary–Adrenal (HPA) axis is also
seen to play a role in the altering of the immune response
characteristics (Klecha et al., 2008).

5. Multiple autoimmune syndrome and
autoimmune polyglandular syndrome
One hint as to the relationship between the various autoimmune
disorders useful here is through the idea of Multiple Autoimmune
Syndrome (MAS) described by Humbert and Dupond (1988). MAS is
the coexistence of 3 or more autoimmune disorders in one individual.
The useful grouping of autoimmune disorders of those that tend to be
present together if they are present is useful in this discussion
(Cojocaru et al., 2010).




Type 1 MAS includes myasthenia gravis, thyoma, polymyositis,
and giant cell myocarditis.
Type 2 MAS includes Sjögrens׳s syndrome, rheumatoid arthritis,
primary cirrhosis, sclerodema, and autoimmune thyroid disease.
Type 3 MAS includes autoimmune thyroid disease, myasthenia
gravis and/or thyoma, Sjögrens׳s syndrome, pernicious anemia,
idiopathic thrombopenic purpura, Addison׳s disease, type 1
diabetes mellitus, vitiligo, SLE, and several others.

Cojocaru et al. (2010) note that in the medical literature, a
dermatological disease, usually vitiligo, is first to be diagnosed, but in
most cases, autoimmune thyroid disease was also present (Ai et al.,
2003). Although diagnosis of the syndrome indicates some genetic or
environmental pre-disposition for autoimmunity, it does suggest that
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in Type 2 and Type 3, that if an autoimmune condition is present, it is
likely that autoimmune thyroid disease is also present – and was likely
present at the time of diagnosis.
It is likely that Type 2 MAS and Type 3 MAS are those
autoimmune diseases where inflammation similar to that in AITD plays
a role. It should be noted that in several autoimmune disorders, e.g.
autoimmune hemolytic anemia and autoimmune thrombocytopenia, do
not seem to require inflammation, although they can be associated
with other autoimmune conditions that do. Also, certainly,
inflammation does not always cause autoimmune disease.
A similar view of the relationship between autoimmune
disorders is through autoimmune polyglandular syndrome where AITD
is considered “Type 2” (Betterle et al., 2004). Type 2 APS is defined by
the occurrence of Addison׳s disease with thyroid autoimmune disease
and/or Type 1 diabetes mellitus. There is some evidence (Krysiak et
al., 2014) that treatment with anti-inflammatory agents may be a
useful treatment in Type 2 APS.

6. Discussion
The leptin levels rise in young girls as they approach puberty
while in boys, leptin declines along with testosterone increase (GarciaMayor et al., 1997). This increase begins a life-long dance between
leptin and low-grade inflammation. Leptin׳s inflammatory effects are
first felt in fat and liver (Li et al., 2006). In the thyroid context, leptin
disrupts the HPT axis controlling thyroid function. Leptin also interferes
with other systems as well. But unlike other systems, the interaction
between thyroid disruption/weight gain and adipose tissue
production/leptin production is unique to the thyroid. Many organs feel
the inflammatory effects of leptin, but the disruption of control along
with the inflammation is likely a unique condition. The dance continues
in postmenopausal women as described by Teixeira et al. (2009)
where serum leptin is elevated in postmenopausal women with
subclinical or overt hyperthyroidism. IL-6 is also seen as elevated in
this population (Siemińska et al., 2010). As events and pathogens that
trigger the PAMP and DAMP response of the thyrocytes over time, the
situation in the thyroid can be ripe for an autoimmune trigger. In men,
with the level of underlying leptin-caused inflammation lower (due to
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leptin and suppressed by testosterone), the thyroid is not in a state
that is as conducive to autoimmunity. An additional factor, not
discussed here, is the relationship between pregnancy and the
triggering of thyroid disruption and autoimmunity – primarily Graves׳
disease (Carney et al., 2014). A further step to the breaking of
tolerance allowing the establishment of an autoimmune disease is
further facilitated by the effect of leptin on regulatory T (Treg cells)
(Matarese et al., 2010), where the Treg numbers are seen to be
inversely correlated with serum leptin.
The specificity of the thyroid to the immune response seems due
to the presence of lymphoid tissue akin to secondary lymphoid follicles
with germinal centers in the thyroid autoimmunity (Armengol et al.,
2001). It is expected that this event happens early in the process after
nonspecific responses result in increased lymphocyte infiltration into
the thyroid (Armengol et al., 2003). A second aspect that makes the
thyroid unique among autoimmune target tissues is that it is the only
one with a hormone (TSH) that stimulates its growth (and increased
thyroid antigens). In addition, CD40 expression in thyrocytes – at least
those that are stressed in some way – allows the thyrocytes to
function as antigen presenting cells. This aspect is implicated for
Graves ׳disease. In Hashimoto׳s the specificity may be also through the
link with CD20 B cells which are both implicated in diabetes initiation
and necessary for the production of spontaneous autoimmune
thyroiditis in mice. B-cell depletion also seems to result in the
production of increased Treg cells (and lower levels of autoimmunity in
mice). So, the nature appears to be both structural and the special
nature of thyroid antigens and markers.
Over time, the thyroid provides an adjuvant-like setting if
specific mimic or self-antigens are present, resulting in autoimmunity
in the thyroid. It is at this time that the molecular mimics described in
the Introduction play a role. The fact that the specific agent or agents
present at the overcoming of tolerance indicate why it has been
difficult to identify a specific one in this case. The nature of this
response will be determined by the agents which triggered the
response and indicated by the anti-thyroid antibodies produced. This
process is summarized in Fig. 1.
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Fig. 1. Diagram of the hypothesized process by which thyroid autoimmunity is
created.

7. Conclusion
The triggers of AITDs discussed contribute to the disease in
many ways with different weights and relative importance. They cause
the hormone deregulation and ultimately result in clinical malfunction
of thyroid. The regulation and physiological responsiveness of the
thyroid are also influenced by many factors, the susceptibility of
thyroid to autoimmunity due to the unique regulation system and
response axis to maintain delicate homeostasis and the structural
integrity. The humoral and cellular immunity are dynamic and
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autoimmunity can also be influenced by a multitude of factors. In
certain circumstances, the predominant status can be fragile,
influenced by one factor which overwhelms the others – affecting the
overall autoimmune balance. Throughout the inflammatory progress
and/or persistent stimulation, secondary autoimmune disorders in
distal relatively resistant organs, such as pancreas, rheumatoid
arthritis, etc. may be seen as starting with a thyroid
malfunction/disorder.
With many mimics and factors, it would seem that the initiation
of AITDs is very complicated – but at its heart, it may very well be a
natural result of inflammation caused by leptin, and the presence of a
trigger through PAMP or DAMP, along with a mimic or cell damage. The
increased incidence in females can be easily seen in this context
through increased leptin. There can be other aspects, suppression
through testosterone in men, and the specifics of a stress response
further shape a complete picture. In individuals with several
autoimmune diseases, it is likely that thyroid autoimmunity also exists
(and likely was existing at the time of the first diagnosis).
With the stage set by 1) inflammation, 2) the ability of the
thyrocytes to respond to patterns, 3) a large collection of mimics and
other agents, and 4) disruption of thyroid and Treg function (and
resulting feedback to adipose tissue), the stage is set for AITDs. And,
a process that results in an increased incidence of AITDs in females.

7.1. Testable hypotheses
Several aspects of this theory are directly testable. Some of the
most critical are listed here.
1) Central to the hypothesis is that inflammation due to leptin is a
contributing agent to the development of AITD. Since there is an
increase in obesity in the US, there should be a shift in the
development of AITD to younger populations. There is a partial
test of this idea in Popławska-Kita et al. (2014) where the Body
Mass Index (BMI) was examined in Hashimoto׳s thyroiditis
patients, both in euthyroid (normal T4 levels) and hypothyroid
conditions. It was found that Hashimoto׳s patients had higher
BMI and fat mass than controls. This is not quite a test as

Journal of Theoretical Biology, Vol 375 (June 21, 2015): pg. 95-100. DOI. This article is © Elsevier and permission has been
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be
further copied/distributed or hosted elsewhere without the express permission from Elsevier.

13

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

disruption of the thyroid hormone can result in weight gain. But
note that the result hold for euthyroid patients as well.
2) The rate of Hashimoto׳s in men should increase along with
increasing obesity. This may involve a description of the level of
obesity needed to generate an increase in the disease.
3) One should find the presence of high concentration of adipokine
inflammatory molecules as predictive for the development of
AITD. This has been explored by Mikoś et al. (2014) who found
that in children, levels of IL-1β, TNF-α, and IL-6 are predictive
of AITD and the level of IL-1β can be specifically used to
distinguish Hashimoto׳s from Graves ׳disease. This was done in
normal and diagnosed (but not treated) children, so it is not a
predictive test.
4) Patients who develop Hashimoto׳s over time subclinical
hypothyroidism should show inflammatory differences, or
differences in BMI from those who do not.
Both obesity and Hashimoto׳s increase post-menopause, but is
Hashimoto׳s caused by obesity (i.e., leptin increasing)? There should
be an easy proof that is likely an epidemiology study not yet
completed. With dramatically increasing obesity rates in the US there
should be a “shift” in Hashimoto׳s from occurring almost exclusively
post-menopause to occurring earlier in life (excluding Graves ׳disease
which occurs by a different mechanism/Ab-mediated receptor
activation). If leptin is critically important then there should also be a
“shift” to more men developing Hashimoto׳s since obesity is also
increasing for males.
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